Core Insights - Elutia Inc. is participating in the inaugural Global BioInnovation Forum during the JP Morgan Healthcare Conference on January 13, 2026, to present its advancements in drug-eluting biomatrix technologies [1][5] Company Overview - Elutia is focused on developing and commercializing drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients [6] - The company aims to address the growing need for implantable technologies, emphasizing its mission to humanize medicine [6] Product Development - Elutia will showcase its NXT-41x program, a next-generation antibiotic-eluting biomatrix designed for plastic and reconstructive surgery, which builds on its established biomatrix technology platform [2] - The NXT-41x program is positioned to meet significant unmet needs in breast reconstruction, where postoperative infection rates can reach up to 25% and serious complications affect one in three patients [4] Expert Involvement - Randy Mills, CEO of Elutia, will present alongside Dr. Christopher Reid, a plastic surgeon with expertise in microsurgery and breast reconstruction, who will discuss strategies to mitigate postoperative complications [3] Industry Context - The Global BioInnovation Forum aims to bring together leaders in biotechnology, digital health, and life sciences to discuss innovations that are shaping the future of healthcare [5]
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery